Tet2 Activity is Modulated by Sirt1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome

Jie Sun,Yinghui Zhu,Zonghui Ding,Haojie Dong,Yimei Feng,Qiang Chen,Xiaochun Yu,Dandan Zhao,Herman Wu,Lifeng Feng,Kaoru Tohyama,Philipp Oberdoerffer,Bin Zhang,Ya-Huei Kuo,Ravi Bhatia,Hongchuan Jin,Guido Marcucci,Ling Li

DOI: https://doi.org/10.1182/blood.v128.22.1053.1053

IF: 20.3

2016-01-01

Blood

Abstract:DNA methylation at cytosine position 5 (5mC) is a genetic modification that regulates gene expression and is critical for cancer initiation and development. The methylcytosine dioxygenase TET2 participates in active DNA demethylation by converting 5mC to 5-hydroxymethylcytosine (5hmC) and its subsequent intermediates thereby regulating gene expression. TET2 gene is frequently mutated in hematological disorders, including 15-25% of myelodysplastic syndrome (MDS) cases. Loss of TET2 function leads to DNA hypermethylation and subsequent dysregulated gene expression in hematopoietic stem cells, and has been considered as an initial step of myeloid malignant transformation including MDS and acute myeloid leukemia (AML). While enzymatic activity of TET2 is well studied, little is known about post-translational modifications (PTMs) that regulate its activity in hematopoietic cells.